CAR-T cell therapy is transforming multiple myeloma care by utilizing a patient\u2019s own genetically modified immune cells to achieve long-term, deep disease remission and significantly improve quality of life. <\/p>\n
For years, multiple myeloma management relied on sequential lines of therapy, moving to the next option only when the previous one failed. The objective was merely to keep the disease under control and delay relapse.<\/p>\n
CAR-T therapy marks a breakthrough by providing long periods of disease-free survival after a single administration. Unlike traditional treatments that remain effective only while being taken, CAR-T involves reintroducing modified lymphocytes that actively recognize and combat cancer cells.<\/p>\n
Hematologists remain cautious about using the term “cure” until long-term observations confirm it. Instead, they focus on functional recovery, where patients live for years without the disease impacting their daily lives.<\/p>\n
A key indicator of treatment efficacy today is achieving minimal residual disease (MRD), where even highly sensitive tests fail to detect any remaining cancer cells. This allows patients to move beyond constant hospitalizations and the burden of chronic illness.<\/p>\n
The therapy involves collecting a patient’s T-cells, which are then genetically modified in a laboratory to target specific tumor cells. Once returned to the patient’s body, these “living drugs” continue to patrol for and eliminate cancer.<\/p>\n
While the infusion itself is a one-time event, the procedure requires careful qualification, complex laboratory preparation, and weeks of post-treatment observation. For many patients, the shift from rigid treatment schedules to normal life is the most significant benefit.<\/p>\n
Despite the success seen in clinical trials, CAR-T therapy for multiple myeloma remains largely inaccessible outside of specialized research settings in Poland. Experts argue that the primary obstacle is the lack of routine public funding for this specific application.<\/p>\n
The medical community continues to advocate for reimbursement, which would allow patients to receive the therapy when it is most effective, rather than relying on the limited availability of clinical trial slots.<\/p>\n","protected":false},"excerpt":{"rendered":"
CAR-T cell therapy is transforming multiple myeloma care by utilizing a patient\u2019s own genetically modified immune cells to achieve long-term, deep disease remission and significantly improve quality of life. A Shift in Treatment Strategy For years, multiple myeloma management relied on sequential lines of therapy, moving to the next option only when the previous one […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wpai_generated_summary":"","footnotes":""},"categories":[44],"tags":[],"class_list":["post-12257","post","type-post","status-publish","format-standard","hentry","category-culture"],"_links":{"self":[{"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/posts\/12257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/comments?post=12257"}],"version-history":[{"count":0,"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/posts\/12257\/revisions"}],"wp:attachment":[{"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/media?parent=12257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/categories?post=12257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bizonews.com\/pl\/wp-json\/wp\/v2\/tags?post=12257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}